U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H33ClN2O5S
Molecular Weight 424.983
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLINDAMYCIN

SMILES

[H][C@@]1(O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O)[C@H](NC(=O)[C@@H]2C[C@@H](CCC)CN2C)[C@H](C)Cl

InChI

InChIKey=KDLRVYVGXIQJDK-AWPVFWJPSA-N
InChI=1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050537s035,050600s013,050615s012lbl.pdf | http://www.rxlist.com/clindamycin-phosphate-topical-solution-drug.htm

Clindamycin phosphate is the prodrug of clindamycin with no antimicrobial activity in vitro but can be rapidly converted in vivo to the parent drug, clindamycin, by phosphatase ester hydrolysis. It is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes; Skin and skin structure infections; Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes; Intra-abdominal infections; Septicemia; Bone and joint infections. Orally and parenterally administered clindamycin has been associated with severe colitis, which may end fatally. Abdominal pain, gastrointestinal disturbances, gram-negative folliculitis, eye pain and contact dermatitis have also been reported in association with the use of topical formulations of clindamycin. Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents

CNS Activity

Curator's Comment: Clindamycin phosphate is the prodrug of clindamycin with no antimicrobial activity in vitro but can be rapidly converted in vivo to the parent drug, clindamycin, by phosphatase ester hydrolysis.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.4928E9
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.4928E9
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.4928E9
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.4928E9
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.4928E9
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.4928E9
Curative
CLEOCIN HYDROCHLORIDE

Approved Use

Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

4.4928E9
Curative
CLEOCIN T

Approved Use

Clindamycin Phosphate is indicated in the treatment of acne vulgaris.

Launch Date

3.31862409E11
Curative
CLEOCIN PHOSPHATE

Approved Use

Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus.

Launch Date

8.6745596E10
Curative
CLEOCIN PHOSPHATE

Approved Use

Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes.

Launch Date

8.6745596E10
Curative
CLEOCIN PHOSPHATE

Approved Use

Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes.

Launch Date

8.6745596E10
Curative
CLEOCIN PHOSPHATE

Approved Use

Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms.

Launch Date

8.6745596E10
Curative
CLEOCIN PHOSPHATE

Approved Use

Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes.

Launch Date

8.6745596E10
Curative
CLEOCIN PHOSPHATE

Approved Use

Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms.

Launch Date

8.6745596E10
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.1 μg/mL
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLINDAMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
0.92 ng/mL
0.03 g 1 times / day steady-state, topical
dose: 0.03 g
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
CLINDAMYCIN plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
12.2 μg × h/mL
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLINDAMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
13.54 ng × h/mL
0.03 g 1 times / day steady-state, topical
dose: 0.03 g
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
CLINDAMYCIN plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.3 h
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLINDAMYCIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
5 g 7 times / day multiple, vaginal
Recommended
Dose: 5 g, 7 times / day
Route: vaginal
Route: multiple
Dose: 5 g, 7 times / day
Sources: Page: p.571
unhealthy, 16 - 51
n = 79
Health Status: unhealthy
Condition: Bacterial Vaginosis
Age Group: 16 - 51
Sex: F
Population Size: 79
Sources: Page: p.571
Disc. AE: Vaginal pain or burning...
AEs leading to
discontinuation/dose reduction:
Vaginal pain or burning (1.2%)
Sources: Page: p.571
1200 mg 4 times / day multiple, intravenous
Recommended
Dose: 1200 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock...
AEs leading to
discontinuation/dose reduction:
Diarrhea, Clostridium difficile
Anaphylactic shock
Hypersensitivity reaction (severe)
Sources:
300 mg 4 times / day multiple, intramuscular
Recommended
Dose: 300 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock...
AEs leading to
discontinuation/dose reduction:
Diarrhea, Clostridium difficile
Anaphylactic shock
Hypersensitivity reaction (severe)
Sources:
300 mg 4 times / day multiple, intravenous
Recommended
Dose: 300 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock...
AEs leading to
discontinuation/dose reduction:
Diarrhea, Clostridium difficile
Anaphylactic shock
Hypersensitivity reaction (severe)
Sources:
450 mg 4 times / day multiple, oral
Recommended
Dose: 450 mg, 4 times / day
Route: oral
Route: multiple
Dose: 450 mg, 4 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources: Page: p.1
Disc. AE: Diarrhea, Clostridium difficile, Reaction skin...
AEs leading to
discontinuation/dose reduction:
Diarrhea, Clostridium difficile
Reaction skin (severe)
Toxic epidermal necrolysis (grade 3-5)
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Vaginal pain or burning 1.2%
Disc. AE
5 g 7 times / day multiple, vaginal
Recommended
Dose: 5 g, 7 times / day
Route: vaginal
Route: multiple
Dose: 5 g, 7 times / day
Sources: Page: p.571
unhealthy, 16 - 51
n = 79
Health Status: unhealthy
Condition: Bacterial Vaginosis
Age Group: 16 - 51
Sex: F
Population Size: 79
Sources: Page: p.571
Anaphylactic shock Disc. AE
1200 mg 4 times / day multiple, intravenous
Recommended
Dose: 1200 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Diarrhea, Clostridium difficile Disc. AE
1200 mg 4 times / day multiple, intravenous
Recommended
Dose: 1200 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Hypersensitivity reaction severe
Disc. AE
1200 mg 4 times / day multiple, intravenous
Recommended
Dose: 1200 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 1200 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Anaphylactic shock Disc. AE
300 mg 4 times / day multiple, intramuscular
Recommended
Dose: 300 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Diarrhea, Clostridium difficile Disc. AE
300 mg 4 times / day multiple, intramuscular
Recommended
Dose: 300 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Hypersensitivity reaction severe
Disc. AE
300 mg 4 times / day multiple, intramuscular
Recommended
Dose: 300 mg, 4 times / day
Route: intramuscular
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Anaphylactic shock Disc. AE
300 mg 4 times / day multiple, intravenous
Recommended
Dose: 300 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Diarrhea, Clostridium difficile Disc. AE
300 mg 4 times / day multiple, intravenous
Recommended
Dose: 300 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Hypersensitivity reaction severe
Disc. AE
300 mg 4 times / day multiple, intravenous
Recommended
Dose: 300 mg, 4 times / day
Route: intravenous
Route: multiple
Dose: 300 mg, 4 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources:
Diarrhea, Clostridium difficile Disc. AE
450 mg 4 times / day multiple, oral
Recommended
Dose: 450 mg, 4 times / day
Route: oral
Route: multiple
Dose: 450 mg, 4 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources: Page: p.1
Toxic epidermal necrolysis grade 3-5
Disc. AE
450 mg 4 times / day multiple, oral
Recommended
Dose: 450 mg, 4 times / day
Route: oral
Route: multiple
Dose: 450 mg, 4 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources: Page: p.1
Reaction skin severe
Disc. AE
450 mg 4 times / day multiple, oral
Recommended
Dose: 450 mg, 4 times / day
Route: oral
Route: multiple
Dose: 450 mg, 4 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci
Sources: Page: p.1
Overview

Overview

Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
likely (co-administration study)
Comment: inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin
Page: 5.0
minor
likely (co-administration study)
Comment: inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin
Page: 5.0
not determined
not determined
not determined
not determined
not determined
not determined
not determined
not determined
PubMed

PubMed

TitleDatePubMed
Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis.
1999 Sep
A simple, efficient and inexpensive program for preventing prematurity.
2001
Occurrence of metronidazole and imipenem resistance among Bacteroides fragilis group clinical isolates in Hungary.
2001
Streptococcal toxic shock syndrome revealed by a peritonitis. Case report and review of the literature.
2001
Lemierre's syndrome with spondylitis and pulmonary and gluteal abscesses associated with Mycoplasma pneumoniae pneumonia.
2001 Apr
Severe babesiosis in Long Island: review of 34 cases and their complications.
2001 Apr 15
Clindamycin suspension and endocarditis prophylaxis.
2001 Apr 28
Incidence of beta-lactamase production and antimicrobial susceptibility of anaerobic gram-negative rods isolated from pus specimens of orofacial odontogenic infections.
2001 Feb
Antimicrobial resistance of Streptococcus pneumoniae isolates in 1999 and 2000 in Madrid, Spain: a multicentre surveillance study.
2001 Feb
[Microbiological and immunological monitoring in polyarticular rheumatoid arthritis after total joint replacement].
2001 Feb 9
[Guidelines for antibiotic prophylaxis of bacterial endocarditis in patients undergoing dental therapy].
2001 Jan
The association of elevated percent bands on admission with failure and complications of interval appendectomy.
2001 Jan
Treatment of dogs infected with Hepatozoon americanum: 53 cases (1989-1998).
2001 Jan 1
Xerostomia, xerophthalmia, and plasmacytic infiltrates of the salivary glands (Sjögren's-like syndrome) in a cat.
2001 Jan 1
The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product.
2001 Jan-Feb
Cutaneous botryomycosis of the cervicofacial region.
2001 Jul
In vitro activity and pharmacodynamics of azithromycin and clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary pharmacokinetics.
2001 Mar
Comparative in-vitro activity of trovafloxacin and other related drugs against isolates of streptococcus oralis.
2001 Mar
Antibiotic-resistant bacteria in pediatric chronic sinusitis.
2001 Mar
Treatment of nosocomial postoperative pneumonia in cancer patients: a prospective randomized study.
2001 Mar
Sequential parapharyngeal abscesses.
2001 Mar
Phenotypic and genotypic characterization of macrolide-resistant group A Streptococcus strains in the province of Quebec, Canada.
2001 Mar
Molecular epidemiology and genetic linkage of macrolide and aminoglycoside resistance in Staphylococcus intermedius of canine origin.
2001 Mar 20
The treatment of babesiosis.
2001 Mar 8
Effect of clindamycin therapy on phagocytic and oxidative activity profiles of spleen mononuclear cells in Babesia rodhaini-infected mice.
2001 May
High prevalence of carriage of antibiotic-resistant Streptococcus pneumoniae in children in Kampala Uganda.
2001 May
When to suspect and how to monitor babesiosis.
2001 May 15
Clindamycin hydrochloride and clindamycin phosphate: two drugs or one? A retrospective analysis of a spontaneous reporting system.
2017 Feb
Patents

Sample Use Guides

150 to 300 mg every 6 hours (Serious infections), 300 to 450 mg every 6 hours (More severe infections), 8 to 16 mg/kg/day divided into three or four equal doses (Serious infections in pediatric patients), 16 to 20 mg/kg/day divided into three or four equal doses (More severe infections in pediatric patients).
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: The Minimum Inhibitory Concentration was 0.03-0.12 ug/ml (Streptococcus pneumoniae ATCC 49619) when testing aerobic pathogens and 0.06-0.25 ug/ml (Eubacterium lentum ATCC 43055) when testing anaerobs.
MIC=0.03-0.12 ug/ml (Aerobic Pathogens), MIC=0.06-0.25 ug/ml (Anaerobes).
Name Type Language
CLINDAMYCIN
HSDB   INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
U-21,251
Code English
clindamycin [INN]
Common Name English
U-21251
Code English
CLINDAMYCIN [MART.]
Common Name English
CLINDAMYCIN [USAN]
Common Name English
CLINDAMYCIN [GREEN BOOK]
Common Name English
Clindamycin [WHO-DD]
Common Name English
METHYL 7-CHLORO-6,7,8-TRIDEOXY-6-(1-METHYL-TRANS-4-PROPYL-L-2-PYRROLIDINECARBOXAMIDO)-1-THIO-L-THREO-.ALPHA.-D-GALACTO-OCTOPYRANOSIDE
Common Name English
7(S)-CHLORO-7-DEOXYLINCOMYCIN
Common Name English
CLINDAMYCIN [VANDF]
Common Name English
CLINDAMYCIN PHOSPHATE IMPURITY E [EP IMPURITY]
Common Name English
CLINDAMYCIN [HSDB]
Common Name English
L-THREO-.ALPHA.-D-GALACTO-OCTOPYRANOSIDE, METHYL 7-CHLORO-6,7,8-TRIDEOXY-6-(((1-METHYL-4-PROPYL-2-PYRROLIDINYL)CARBONYL)AMINO)-1-THIO-, (2S-TRANS)-
Common Name English
CLINDAMYCIN [MI]
Common Name English
Classification Tree Code System Code
WHO-VATC QD10AF01
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
CFR 21 CFR 520.447
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
WHO-ATC J01FF01
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
WHO-VATC QJ01FF01
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
NDF-RT N0000175442
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
WHO-ATC G01AA10
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
CFR 21 CFR 520.446
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
WHO-ATC D10AF51
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
LIVERTOX NBK548292
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
NDF-RT N0000175442
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
NDF-RT N0000175443
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
WHO-VATC QG01AA10
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
WHO-ATC D10AF01
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
FDA ORPHAN DRUG 26988
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
NDF-RT N0000009982
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.2.2
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
NCI_THESAURUS C82922
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
FDA ORPHAN DRUG 27088
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
WHO-VATC QD10AF51
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
Code System Code Type Description
CHEBI
3745
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
PRIMARY
LACTMED
Clindamycin
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
PRIMARY
INN
2550
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
PRIMARY
WIKIPEDIA
CLINDAMYCIN
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
PRIMARY
MERCK INDEX
m3624
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
PRIMARY Merck Index
FDA UNII
3U02EL437C
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
PRIMARY
EPA CompTox
DTXSID2022836
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
PRIMARY
DRUG CENTRAL
678
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
PRIMARY
CAS
18323-44-9
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
PRIMARY
NCI_THESAURUS
C377
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
PRIMARY
SMS_ID
100000084276
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
PRIMARY
EVMPD
SUB06665MIG
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
PRIMARY
ECHA (EC/EINECS)
242-209-1
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
PRIMARY
MESH
D002981
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
PRIMARY
DAILYMED
3U02EL437C
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
PRIMARY
ChEMBL
CHEMBL1753
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
PRIMARY
PUBCHEM
446598
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
PRIMARY
RXCUI
2582
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
PRIMARY RxNorm
HSDB
3037
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
PRIMARY
DRUG BANK
DB01190
Created by admin on Sat Dec 16 15:52:54 UTC 2023 , Edited by admin on Sat Dec 16 15:52:54 UTC 2023
PRIMARY